Advances in our understanding of ethiology and pathogenesis of psoriasis resulted in the development of novel biologic agents. Experience of clinical use of biologic agents showed certain disadvantages of these medications, i.e. primary inefficacy in a proportion of patients, escape phenomen, and safety issues. An article reviews the clinical studies of secukinumab, a monoclonal antibody to IL-17A, in patients with psoriasis and psoriatic arthritis.
Psoriasis, psoriatic arthritis, systemic inflammation, biologic agents, IL-17A antagonist, secukinumab, safety.